Agenda

6:30pm-8:00pm

Welcome Reception

8:00am-8:10am

Introduction and Meeting Objectives
John Gribben

8:10am-9:50am

Session 1: T-cell lymphoma
Chairs: Laurence de Leval & Francine Foss

• Intestinal T-cell lymphoproliferative disorders; Laurence de Leval
• Experience with the management of enteropathy-associated
  T-cell lymphomas and refractory celiac disease; David Sibon
• Genetics and epigenetics of T-PLL; Reiner Siebert
• AUTO4 CAR-T in T-cell lymphoma; Kate Cwynarski
• Epigenetic drugs in T-cell lymphoma; François Lemonnier
• What is new in the treatment of cutaneous T-cell lymphomas; Steven Horwitz
  Panel Discussion

9:50am-10:10am

Break

10:10am-11:45am

Session 2: Immunotherapy of lymphoma
Chairs: Stephen Ansell & John Gribben

Overview lecture: Engaging the innate & adaptive antitumor immune response in lymphoma; Stephen Ansell

• CAR-T and the tumor microenvironment – DLBCL as a model; John Kuruvilla
• IMiDs in combination; Francisco Hernandez-Ilizaliturri
• Checkpoint inhibitors; Gaël Roué
• Salvage and bridging treatments in R/R LBCL; Georg Lenz
• Double-hit lymphoma – optimizing therapy; Kieron Dunleavy
  Panel Discussion

11:45am-12:30pm

Session 3: Keynote address – Mantle cell lymphoma; Elias Campo
Chair & Introduction; Reiner Siebert

Panel Discussion

12:30pm-1:30pm

Lunch

1:30pm-2:50pm

Session 4: Management of follicular lymphoma beyond first-line therapy
Chairs: Laura Pasqualucci & Jessica Okosun

• Epigenetic alterations in the development of FL; Jessica Okosun
• Transformed FL treatment options; Anna Sureda
• Prognostic factors in patients with relapsed or refractory disease; Laura Pasqualucci
• Mechanisms of action and opportunities for synergy in FL-directed therapies; David Qualls
• How do I sequence therapy for follicular lymphoma? Gilles Salles
  Panel Discussion

2:50pm-4:20pm

Session 5: T-cell therapies for lymphoma
Chairs: Catherine Bollard & David Maloney 

• CD19-CAR-T – real-world experience (commercial CARs); Jeremy Abramson
• CD19-CAR-T – next-generation CD19-CAR-T (Humanized CARs, allo ‘off-the-shelf” CARs etc); David Maloney
• CD20-CAR-T; Mazyar Shadman
• CD30 CAR-T; Barbara Savoldo
• CAR-T for T-cell lymphoid malignancies – using T-ALL as an example; Maksim Mamonkin
• Third party EBV T-cells for EBV lymphomas; Catherine Bollard
  Panel Discussion

4:20pm-4:40pm

Break

4:40pm-5:50pm

Session 6: Novel therapies part 1
Chairs:  Laurie Sehn & Jason Westin

ADCs:

• POLARIX – Polatuzumab vedotin; Laurie Sehn
• Loncastuximab Tesirine; Carmelo Carlo-Stella
• ADCT–301 – Camidanlumab tesirine; Graham Collins
• Brentuximab vedotin; David Straus
  Panel Discussion

5:50pm-6:00pm

Day 1 wrap-up and close

7:00pm

Faculty Dinner

7:30am-8:30am

Breakfast

8:30am-9:50am

Session 6: Novel therapies part 2
Chairs: Marion Subklewe & Carmelo Carlo-Stella 

CD20/CD3 bispecific antibodies: How to choose?

• Redirecting T-cell activity with Anti-BCMA/Anti-CD3 bispecific antibodies in CLL; Arnon Kater
• Mosunetuzumab; Loretta Nastoupil
• Odronextamab (REGN1979); Rajat Bannerji
• DuoBody-CD3xCD20 (Epcoritamab); Stephen Schuster
  Panel Discussion

9:50am-10:10am

Break

10:10am-11:30am

Session 7: BTK inhibitors
Chairs: Loretta Nastoupil & Marek Trněný                                                            

Established and novel  BTK inhibitors: how to choose?

• Ibrutinib combinations; Loretta Nastoupil
• Zanubrutinib; Alessandra Tedeschi
• Acalabrutinib; Marek Trněný
• Pirtobrutinib (LOXO-305); Anthony Mato
  Panel Discussion

11:30am-12:20pm

Session 8: Point/counterpoint – BiTEs versus CARs for NHL
Chairs: Catherine Bollard & David Maloney

• Point: CAR-T for NHL; Jason Westin
• Counterpoint: BiTEs for NHL; Marion Subklewe
  Panel Discussion     

12:20pm-12:30pm

Final Meeting Summary & Conclusions
iwNHL Committee

12:30pm

Lunch